Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project ... from routine lab tests to sequence up ...

NEW YORK, Jan 13 (Reuters ... and health in unprecedented detail,” Regeneron executive Aris Baras, said in a press release. During routine lab tests, the project's healthcare partners will ...

The market rose in the third quarter, reaching new peaks ... A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ...

DNA sequencing company Illumina and biotech Regeneron have invested in electronic ... held Truveta has a valuation exceeding $1bn. The new Truveta Genome Project initiative aims to generate ...

Illumina and Regeneron are taking stakes in health data ... millions by analyzing the leftover specimens taken from routine lab tests. The goal is to build the most diverse database possible ...